| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0bf7b82e0f0ef387acf43f2ddd705ccf |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-485
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2027
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2031
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-137
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2009
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2013
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2018
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2054
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-209
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0053 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-485
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-137 |
| filingDate |
2015-08-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b74489c4b7b2681b0c9726df474ca28d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b4f439a557b2e562c15a64099563fdbc
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a21f5f1937e0dd9bd90b917ca019fe14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_587af3ea6ee6c85cea2c8866ca76cf45 |
| publicationDate |
2016-06-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2016158221-A1 |
| titleOfInvention |
Sustained release formulation of naltrexone |
| abstract |
A sustained-release oral dosage form of naltrexone or a pharmaceutically acceptable salt thereof is provided. The oral dosage form may be administered with another compound. Administration of the oral dosage form may reduce a side effect, which may be a side effect at least partially attributable to a weight-loss treatment. The oral dosage form may be administered to treat a weight-loss condition. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11033543-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10238647-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9633575-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10322121-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11324741-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10403170-B2 |
| priorityDate |
2006-06-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |